Boasting A 42% Return On Equity, Is Delorean Corporation Limited (ASX:DEL) A Top Quality Stock?
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
How Do You Calculate Return On Equity?
The formula for return on equity is:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Delorean is:
42% = AU$5.3m ÷ AU$12m (Based on the trailing twelve months to December 2024).
The 'return' is the profit over the last twelve months. That means that for every A$1 worth of shareholders' equity, the company generated A$0.42 in profit.
See our latest analysis for Delorean
Does Delorean Have A Good Return On Equity?
By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As is clear from the image below, Delorean has a better ROE than the average (12%) in the Renewable Energy industry.
That is a good sign. With that said, a high ROE doesn't always indicate high profitability. Aside from changes in net income, a high ROE can also be the outcome of high debt relative to equity, which indicates risk. To know the 2 risks we have identified for Delorean visit our risks dashboard for free.
How Does Debt Impact Return On Equity?
Most companies need money -- from somewhere -- to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.
Delorean's Debt And Its 42% ROE
It's worth noting the high use of debt by Delorean, leading to its debt to equity ratio of 1.26. Its ROE is pretty impressive but, it would have probably been lower without the use of debt. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it.
Conclusion
Return on equity is one way we can compare its business quality of different companies. A company that can achieve a high return on equity without debt could be considered a high quality business. All else being equal, a higher ROE is better.
Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. Profit growth rates, versus the expectations reflected in the price of the stock, are a particularly important to consider. You can see how the company has grow in the past by looking at this FREE detailed graph of past earnings, revenue and cash flow.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –
Yahoo
13 minutes ago
- Yahoo
Skyworks Sets Date for Third Quarter Fiscal 2025 Earnings Release and Conference Call
Aug. 5 at 4:30 p.m. EDT IRVINE, Calif., July 22, 2025--(BUSINESS WIRE)--Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, will host a conference call with analysts to discuss its third quarter fiscal 2025 results and business outlook on Aug. 5, 2025, at 4:30 p.m. EDT. After the close of the market on Aug. 5, and prior to the conference call, Skyworks will issue a copy of the earnings press release via Business Wire. The press release may also be viewed on Skyworks' website at To listen to the conference call, please visit the investor relations section of Skyworks' website at Playback of the conference call will be available on Skyworks' website at beginning at 9 p.m. EDT on Aug. 5, 2025. Additionally, a transcript of the company's prepared remarks will be made available on our website promptly after their conclusion during the call. About Skyworks Skyworks Solutions, Inc. is empowering the wireless networking revolution. Our highly innovative analog and mixed-signal semiconductors are connecting people, places and things spanning a number of new and previously unimagined applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables. Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit Skyworks' website at: Safe Harbor Statement Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as "anticipates," "expects," "forecasts," "intends," "believes," "plans," "may," "will" or "continue," and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties, including those identified in the "Risk Factors" section of Skyworks' most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission ("SEC"). Copies of Skyworks' SEC filings can be obtained, free of charge, on Skyworks' website ( or at the SEC's website ( Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners. View source version on Contacts Media Relations: Constance Griffiths(949) Investor Relations: Raji Gill(949) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
As Bitcoin and Ethereum Soar, Should Investors Hop Onto the Crypto Train or Wait for Prices to Drop?
Key Points It's reasonable to be hesitant about buying during a powerful rally. That doesn't mean you should always avoid doing it. Waiting for lower prices is a choice that does not always pay off. 10 stocks we like better than Bitcoin › The cryptocurrency markets are having an absolutely sizzling summer. Bitcoin (CRYPTO: BTC) recently topped $123,000, Ethereum (CRYPTO: ETH) vaulted above $3,700, and Solana (CRYPTO: SOL) trades for more than $195 after a steep climb. All three coins are up between 34% and 137% in just the past three months, with Ethereum being the pacesetter and Solana and Bitcoin the runners-up. That kind of linked movement raises a classic dilemma for investors: Is it smarter to chase the strength and buy coins now, or wait for the inevitable pullback? History says crypto does deliver violent corrections regularly, yet it has also said that sidelining cash during bull markets has cost investors much more than the subsequent crashes ever did. Let's shed some more light on this issue and determine what the best course of action is. The rally still has legs The macroeconomic and monetary factors at play today all point toward the crypto sector's bull run having plenty of juice left. First, central banks from Europe to China are already cutting their interest rates, thereby reducing the cost of borrowing and increasing liquidity, and there is likely to be more easing through the end of the year, potentially in the U.S. as well. Cheaper money usually finds its way into risk assets like crypto, which tends to act like a levered bet on that rising tide. Second, institutional demand is here, and it's powerful. June saw $4.6 billion worth of inflows into Bitcoin exchange-traded funds (ETFs), propelling the coin to record highs. The same institutional desks are now green‑lighting Ethereum allocations, and other cryptocurrencies may soon be on the docket as well. Newfound regulatory clarity might be the strongest accelerant of all here. On July 18, the Guiding and Establishing National Innovation for U.S. Stablecoins Act (Genius Act for short) was signed into law, thereby providing a legal framework for bank‑issued stablecoins. The industry's biggest policy overhang of the past five years is finally starting to abate. Lastly, momentum is broadening beyond the big two coins. Solana's tokenized real‑world asset (RWA) value has jumped 140% year to date to reach more than $418 million as of July 14. That's double the growth rate of the wider RWA market. Much of that spike comes from xStocks, a joint venture between two of the biggest centralized cryptocurrency exchanges -- Kraken and Bybit -- that now lists 60 tokenized U.S. equities tradable 24/7 with instant on‑chain settlement. Growing uses like these reinforce the idea that crypto's sandbox is turning into real infrastructure, and capital is already flowing in to reflect the change. How to climb aboard without losing sleep It's no secret that rallies of this size generate fear of missing out (FOMO) and its shadow, regret. Resisting FOMO is key, especially if you accept that this rally is nowhere close to being over -- impulsive buying can easily lead to disaster. Crypto remains habitually volatile. Assuming you jump in with a lump sum at the wrong moment, a routine flash crash can sting hard enough to force an ill‑timed exit. And, generally speaking, investing without a long-term plan for how to manage the investment is a recipe for heartache. Don't assume that this uptrend will last long enough to make you rich, because it will not. Instead, now is a great time for dollar-cost averaging (DCA). Buy a set dollar amount of your preferred coins on a schedule, and you will smooth your entry price across bull and bear stretches alike. Over multiyear horizons, it reduces the chance that short‑term volatility leads you to make an actual investing mistake. This method does not eliminate risk. Bitcoin fell very sharply in 2022, and a similar drawdown will happen again. But if your horizon is five years or more, the probability of negative returns shrinks dramatically, especially when underlying adoption and policy support keep expanding. In closing, crypto's train is already leaving the station, and it may be hauling new cars behind it for a while. Stepping aboard with discipline beats waving from the platform hoping for a cheaper ticket. Don't worry if you don't hop on at the perfect moment -- it's the direction of travel that matters the most. Do the experts think Bitcoin is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Bitcoin make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,048% vs. just 180% for the S&P — that is beating the market by 867.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Alex Carchidi has positions in Bitcoin, Ethereum, and Solana. The Motley Fool has positions in and recommends Bitcoin, Ethereum, and Solana. The Motley Fool has a disclosure policy. As Bitcoin and Ethereum Soar, Should Investors Hop Onto the Crypto Train or Wait for Prices to Drop? was originally published by The Motley Fool Sign in to access your portfolio